 PLANEGGMUNICH, GERMANY and MONTREAL, QC ACCESSWIRE January 12, 2021 MorphoSys AG FSE:MOR; Prime Standard Segment; MDAX TecDAX; NASDAQ:MOR and Incyte NASDAQ:INCY today announced that Health Canada has accepted the New Drug Submission NDS for tafasitamab, an anti-CD19 antibody. The application seeks approval of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma DLBCL, including DLBCL arising from low grade lymphoma, who are not eligible for, or refuse, autologous stem cell transplant ASCT. 